merged_alzheimers-treatment-kisunla-donanemab.txt
<question_number>1</question_number>  
<answer>Some experts say they may not slow decline enough to be noticeable to patients or families, and some Alzheimer's experts are skeptical of the anti-amyloid drugs and said they believed the risks outweighed the potential for a slight benefit.</answer>  

<question_number>2</question_number>  
<answer>Some experts worry that emphasis on anti-amyloid drugs might discourage patients from participating in trials for treatments that could be better.</answer>  

<question_number>3</question_number>  
<answer>Dr. Greicius said there's no correlation in any of their studies between the removal of amyloid plaques and the clinical response in individual subjects.</answer>  

<question_number>4</question_number>  
<answer>The donanemab trial had higher rates of swelling and bleeding than the Leqembi trial, which could impact the perception of Kisunla's safety.</answer>  

<question_number>5</question_number>  
<answer>The higher price reflects the expectation that patients can stop Kisunla after their plaques are cleared, potentially reducing overall cost and inconvenience.</answer>  

<question_number>6</question_number>  
<answer>Some patients decided against starting anti-amyloid drugs as soon as they heard anything about brain swelling or edema being a risk at all.</answer>  

<question_number>7</question_number>  
<answer>Kisunla can be stopped after amyloid is cleared, which could reduce the overall cost and inconvenience of the treatment as well as the risk of side effects.</answer>  

<question_number>8</question_number>  
<answer>Amyloid</answer>  

<question_number>9</question_number>  
<answer>Dr. Michael Greicius</answer>  

<question_number>10</question_number>  
<answer>Trial participants with intermediate tau levels declined more slowly on donanemab than those with high levels, suggesting that treating patients earlier was more effective.</answer>